On May 30, 2024, Salvatore Privitera, Chief Technical Officer of AtriCure Inc (NASDAQ:ATRC), purchased 5,000 shares of the company, as reported in a recent SEC Filing.
MASON, Ohio, May 15, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Leerink Partners Healthcare Crossroads Conference.
Shareholders might have noticed that AtriCure, Inc. ( NASDAQ:ATRC ) filed its first-quarter result this time last week...